for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nantkwest Inc

NK.OQ

Latest Trade

1.20USD

Change

-0.05(-4.00%)

Volume

17,790

Today's Range

1.18

 - 

1.26

52 Week Range

0.93

 - 

4.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.25
Open
1.24
Volume
17,790
3M AVG Volume
3.17
Today's High
1.26
Today's Low
1.18
52 Week High
4.08
52 Week Low
0.93
Shares Out (MIL)
98.31
Market Cap (MIL)
122.88
Forward P/E
-1.69
Dividend (Yield %)
--

Latest Developments

More

Nantkwest Inc Files For Mixed Shelf Of Up To $300 Mln

Nantkwest Inc Says CEO Exercised Warrants With An Exercise Price Of $1.9984 & Options With An Exercise Price Of $2.1983

Nantkwest Names Sonja Nelson Chief Financial Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nantkwest Inc

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.

Industry

Biotechnology & Drugs

Contact Info

3530 John Hopkins Ct

+1.858.6330300

https://www.nantkwest.com/

Executive Leadership

Patrick Soon-Shiong

Chairman of the Board, Chief Executive Officer

Barry J. Simon

President, Chief Administrative Officer, Director

Steven Gorlin

Vice Chairman of the Board

Sonja Nelson

Chief Financial Officer

Cheryl L. Cohen

Director

Key Stats

4.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.470

2017

-1.200

2018

-1.220

2019(E)

-0.739
Price To Earnings (TTM)
--
Price To Sales (TTM)
2,048.08
Price To Book (MRQ)
0.81
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-42.62
Return on Equity (TTM)
-39.03

Latest News

Latest News

BRIEF-Nantkwest announces publication of preclinical data of hank cell therapy

* Nantkwest announces publication of preclinical data of hank cell therapy in combination with checkpoint inhibitor avelumab providing strong rationale for advancement to human clinical trials Source text for Eikon: Further company coverage:

BRIEF-NantKwest expands nant cancer vaccine program

* NantKwest expands nant cancer vaccine program with additional clinical trials announced addressing multiple cancer types across all stages of disease

BRIEF-Nantkwest and Nantcell announce FDA authorization for Nant Cancer vaccine clinical trials

* Nantkwest and nantcell announce fda authorization for the nant cancer vaccine clinical trials, the first novel combination of innate and adaptive immunotherapy in patients with pancreatic cancer Source text for Eikon: Further company coverage:

BRIEF-NantKwest and Viracta Therapeutics report series B financing

* NantKwest and Viracta Therapeutics announce series b financing and immunotherapy partnership

BRIEF-Nantkwest announces FDA grant of orphan drug designation

* Nantkwest announces FDA grant of orphan drug designation for the company's ank natural killer cell therapy in merkel cell carcinoma Source text for Eikon: Further company coverage:

BRIEF-NantKwest says FDA authorized co's IND for early-stage study

* NantKwest - U.S. FDA has authorized co's IND for its first-in-human, high-affinity natural killer (haNK) cell therapy Phase I clinical study Source text for Eikon: Further company coverage:

BRIEF-Altor Bioscience and NantKwest announces co-development agreement

* Development agreement to advance innovative natural killer cell combination immunotherapies for the treatment of cancer

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up